List of works - Roberto Pili

A liquid chromatography/tandem mass spectrometry assay to quantitate MS-275 in human plasma.

scientific article published on 12 September 2006

A phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone

scientific article

A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer

scientific article

A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC).

scientific article

A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate ⬇️

scientific article published on December 22, 2010

A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer

scientific article

Acquired tumor cell resistance to sunitinib causes resistance in a HT-29 human colon cancer xenograft mouse model without affecting sunitinib biodistribution or the tumor microvasculature

scientific article

An open-label study to determine the maximum tolerated dose of the multitargeted tyrosine kinase inhibitor CEP-11981 in patients with advanced cancer

scientific article

Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination

scientific article

Class I Histone Deacetylase Inhibitor Entinostat Suppresses Regulatory T Cells and Enhances Immunotherapies in Renal and Prostate Cancer Models ⬇️

scientific article published on January 27, 2012

Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial

scientific article

Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models

scientific article

Concurrent HDAC and mTORC1 Inhibition Attenuate Androgen Receptor and Hypoxia Signaling Associated with Alterations in MicroRNA Expression ⬇️

scientific article published on November 7, 2011

Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth

scientific article

Dll4 blockade potentiates the anti-tumor effects of VEGF inhibition in renal cell carcinoma patient-derived xenografts

scientific article

Generation of a syngeneic orthotopic transplant model of prostate cancer metastasis

scientific article

HDAC 1 and 6 modulate cell invasion and migration in clear cell renal cell carcinoma

scientific article

High-dose interleukin-2 therapy for metastatic renal cell carcinoma: a contemporary experience

scientific article

Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies ⬇️

scientific article published on August 1, 2010

Histone deacetylase inhibitors and epigenetic modifications as a novel strategy in renal cell carcinoma

scientific article

Id1 regulates angiogenesis through transcriptional repression of thrombospondin-1

scientific journal article

Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer

scientific article

Identification of type 1 inosine monophosphate dehydrogenase as an antiangiogenic drug target

scientific article

Induction of cell cycle arrest and DNA damage by the HDAC inhibitor panobinostat (LBH589) and the lipid peroxidation end product 4-hydroxynonenal in prostate cancer cells ⬇️

scientific article published on November 13, 2010

Inhibition of Hsp90 augments docetaxel therapy in castrate resistant prostate cancer

scientific article

Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance.

scientific article published on 6 October 2011

Mechanism of action and clinical activity of tasquinimod in castrate-resistant prostate cancer

scientific article

Multimodal imaging guided preclinical trials of vascular targeting in prostate cancer

scientific article

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

scientific article (publication date: August 2009)

Pentastatin-1, a collagen IV derived 20-mer peptide, suppresses tumor growth in a small cell lung cancer xenograft model

scientific article

Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinoma

scientific article published on 25 October 2019

Phase II Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer ⬇️

scientific article published on September 19, 2011

Phase II evaluation of docetaxel plus exisulind in patients with androgen independent prostate carcinoma.

scientific article published in August 2006

Phase II study on the addition of ASA404 (vadimezan; 5,6-dimethylxanthenone-4-acetic acid) to docetaxel in CRMPC

scientific article

Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer

scientific article

Preclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpoint

scientific article

Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition ⬇️

scientific article published on July 17, 2012

Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study

scientific article

Selenomethionine and methyl selenocysteine: multiple-dose pharmacokinetics in selenium-replete men.

scientific article

Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications

scientific article

Symptoms, supportive care needs, and function in cancer patients: how are they related?

scientific article

Tasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine models

scientific article

The N-Myc down regulated Gene1 (NDRG1) Is a Rab4a effector involved in vesicular recycling of E-cadherin

scientific article

Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer

scientific article published on February 2015

Use of a glycolipid inhibitor to ameliorate renal cancer in a mouse model

scientific article

Vascular Disruption in Combination with mTOR Inhibition in Renal Cell Carcinoma ⬇️

scientific article published on November 14, 2011

Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium [...]

scientific article

List of works by Roberto Pili

A liquid chromatography/tandem mass spectrometry assay to quantitate MS-275 in human plasma.

A phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone

A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer

A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC).

A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate ⬇️

A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer

Acquired tumor cell resistance to sunitinib causes resistance in a HT-29 human colon cancer xenograft mouse model without affecting sunitinib biodistribution or the tumor microvasculature

An open-label study to determine the maximum tolerated dose of the multitargeted tyrosine kinase inhibitor CEP-11981 in patients with advanced cancer

Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination

Class I Histone Deacetylase Inhibitor Entinostat Suppresses Regulatory T Cells and Enhances Immunotherapies in Renal and Prostate Cancer Models ⬇️

Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial

Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models

Concurrent HDAC and mTORC1 Inhibition Attenuate Androgen Receptor and Hypoxia Signaling Associated with Alterations in MicroRNA Expression ⬇️

Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth

Dll4 blockade potentiates the anti-tumor effects of VEGF inhibition in renal cell carcinoma patient-derived xenografts

Generation of a syngeneic orthotopic transplant model of prostate cancer metastasis

HDAC 1 and 6 modulate cell invasion and migration in clear cell renal cell carcinoma

High-dose interleukin-2 therapy for metastatic renal cell carcinoma: a contemporary experience

Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies ⬇️

Histone deacetylase inhibitors and epigenetic modifications as a novel strategy in renal cell carcinoma

Id1 regulates angiogenesis through transcriptional repression of thrombospondin-1

Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer

Identification of type 1 inosine monophosphate dehydrogenase as an antiangiogenic drug target

Induction of cell cycle arrest and DNA damage by the HDAC inhibitor panobinostat (LBH589) and the lipid peroxidation end product 4-hydroxynonenal in prostate cancer cells ⬇️

Inhibition of Hsp90 augments docetaxel therapy in castrate resistant prostate cancer

Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance.

Mechanism of action and clinical activity of tasquinimod in castrate-resistant prostate cancer

Multimodal imaging guided preclinical trials of vascular targeting in prostate cancer

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

Pentastatin-1, a collagen IV derived 20-mer peptide, suppresses tumor growth in a small cell lung cancer xenograft model

Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinoma

Phase II Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer ⬇️

Phase II evaluation of docetaxel plus exisulind in patients with androgen independent prostate carcinoma.

Phase II study on the addition of ASA404 (vadimezan; 5,6-dimethylxanthenone-4-acetic acid) to docetaxel in CRMPC

Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer

Preclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpoint

Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition ⬇️

Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study

Selenomethionine and methyl selenocysteine: multiple-dose pharmacokinetics in selenium-replete men.

Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications

Symptoms, supportive care needs, and function in cancer patients: how are they related?

Tasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine models

The N-Myc down regulated Gene1 (NDRG1) Is a Rab4a effector involved in vesicular recycling of E-cadherin

Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer

Use of a glycolipid inhibitor to ameliorate renal cancer in a mouse model

Vascular Disruption in Combination with mTOR Inhibition in Renal Cell Carcinoma ⬇️

Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium [...]